Bob, I was on a three year phase 3 trial of Bydureon and am on it again since it has been approved. It is not a fast acting insulin and is not a competitor to Afrezza.

Amylin sold at $31.00 per share. Probably less than they should have, but they lacked the ability to market Bydureon and had substantial debt thanks to delays by the FDA.

I believe trying to draw a comparison between Amylin and MNKD is like comparing apples to oranges. MNKD has much, much more potential to help diabetics worldwide.